{"entity":{"id":"adc-cdmo-manufacturing","kind":"technology","name":"ADC bioconjugation manufacturing (CDMOs)","aka":[],"tldr":"ADC bioconjugation manufacturing joins a payload so toxic it needs the top containment class (OEB 5) to an antibody, then checks drug-to-antibody ratio and free payload. Capacity sits with a handful of contractors such as Lonza, WuXi XDC and Samsung Biologics, so long queues and China-based exposure shape who can develop ADCs.","summary":"ADC manufacturing needs high-potency containment (OEB 5), conjugation chemistry, and analytics for drug-to-antibody ratio and free payload. Capacity is concentrated in a handful of CDMOs: Lonza (Visp, incl. Synaffix technology), WuXi XDC, Samsung Biologics (new ADC plant 2025), Piramal Pharma Solutions, Abzena, Sterling, and Merck KGaA's MilliporeSigma. Payload-linker supply (MedChemExpress, Levena, Kelun's in-house) and lyophilised fill-finish are the other choke points.","status":"established","asOf":"2026-09-08","links":[{"label":"21 CFR Part 211: current good manufacturing practice for finished pharmaceuticals","url":"https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-211"}],"tags":["supporting"],"related":[],"cancers":[],"sections":["adcs"],"technologies":["adc","site-specific-conjugation"],"targets":[],"drugs":[],"companies":["lonza","wuxi-xdc","samsung-biologics","piramal-pharma-solutions","abzena","synaffix"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"principle":"Antibody produced by CHO cell culture; payload-linker synthesised under containment; site-specific or stochastic conjugation, purification, and DAR analytics; aseptic fill.","strengths":["Specialised containment and analytics","Integrated antibody-to-vial programmes"],"limitations":["Few qualified sites, long queues","Geopolitical exposure (China-based capacity)","Payload-linker single sourcing"]},"route":"/technologies/adc-cdmo-manufacturing/","neighbours":{"section":[{"id":"adcs","kind":"section","name":"Antibody-Drug Conjugates","route":"/fronts/adcs/"}],"technology":[{"id":"monoclonal-antibody-manufacturing","kind":"technology","name":"Antibody manufacturing (CHO bioprocessing)","route":"/technologies/monoclonal-antibody-manufacturing/"},{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"},{"id":"downstream-purification-chromatography","kind":"technology","name":"Downstream purification (Protein A capture, viral clearance, polishing)","route":"/technologies/downstream-purification-chromatography/"},{"id":"high-potency-payload-synthesis","kind":"technology","name":"Payload-linker synthesis (high-potency API)","route":"/technologies/high-potency-payload-synthesis/"},{"id":"site-specific-conjugation","kind":"technology","name":"Site-specific conjugation & linker chemistry","route":"/technologies/site-specific-conjugation/"},{"id":"adc-supply-chain","kind":"technology","name":"The ADC supply chain (antibody, payload-linker, conjugation, fill)","route":"/technologies/adc-supply-chain/"}],"company":[{"id":"abzena","kind":"company","name":"Abzena","route":"/companies/abzena/"},{"id":"lonza","kind":"company","name":"Lonza","route":"/companies/lonza/"},{"id":"piramal-pharma-solutions","kind":"company","name":"Piramal Pharma Solutions","route":"/companies/piramal-pharma-solutions/"},{"id":"samsung-biologics","kind":"company","name":"Samsung Biologics","route":"/companies/samsung-biologics/"},{"id":"sterling-pharma-solutions","kind":"company","name":"Sterling Pharma Solutions","route":"/companies/sterling-pharma-solutions/"},{"id":"synaffix","kind":"company","name":"Synaffix (Lonza)","route":"/companies/synaffix/"},{"id":"wuxi-xdc","kind":"company","name":"WuXi XDC","route":"/companies/wuxi-xdc/"}],"term":[{"id":"biosecure-act","kind":"term","name":"BIOSECURE Act","route":"/terms/biosecure-act/"},{"id":"cdmo","kind":"term","name":"CDMO (contract development and manufacturing organisation)","route":"/terms/cdmo/"}]}}